Li Fengying, Xie Xinyou, Ren Xiaobin, Zhang Jun
Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 Qing-chun East Road, Hangzhou, 310016, People's Republic of China.
Department of Prevention and Control of Infectious Diseases, Hangzhou Municipal Center for Disease Control and Prevention, 568 Mingshi Road, Hangzhou, 310021, People's Republic of China.
Cancer Chemother Pharmacol. 2016 Jun;77(6):1183-91. doi: 10.1007/s00280-016-3015-9. Epub 2016 Apr 21.
This meta-analysis aimed to evaluate whether an association exists between the ERCC1 rs11615 (C>T) polymorphism and patient response to platinum-based chemotherapy and radiation-based chemotherapy.
Publications were selected from PubMed and MEDLINE. A meta-analysis was conducted to determine the association between genetic polymorphisms and response to platinum-based chemotherapy and radiation-based chemotherapy by checking the odds ratios (ORs) and 95 % confidence intervals (CIs).
In our overall analysis, the ERCC1 rs11615 (C>T) polymorphism was not associated with response to platinum-based chemotherapy in five comparison models. In the subgroup analyses by ethnicity, the ERCC1 rs11615 (C>T) polymorphism was shown to be significantly associated with objective response in Caucasian patients treated with platinum-based chemotherapy in the recessive model (TT vs.
CT/CC: OR 0.696, 95 % CI 0.508-0.954, heterogeneity = 0.330), but the association was not observed in the Asian population. The C allele was significantly associated with better response to radiochemotherapy in the recessive model comparison (TT vs.
CC/CT: OR 0.724, 95 % CI 0.585-0.869, heterogeneity = 0.008). Subgroup analysis by cancer type revealed that the C allele of ERCC1 rs11615 predicted a better response in esophageal cancers in two comparison models (T vs. C: OR 0.756, 95 % CI 0.648-0.880, heterogeneity = 0.653; TT vs.
TC/CC: OR 0.457, 95 % CI 0.306-0.684, heterogeneity = 0.723). Stratified analysis by ethnicity showed a better response in Caucasians in allelic comparison model (T vs. C: OR 0.895, 95 % CI 0.819-0.977, heterogeneity = 0.095).
Together, our results suggest that the ERCC1 rs11615 (C>T) polymorphism was associated with therapeutic response in Caucasian patients and C allele of ERCC1 rs11615 could represent a genetic molecular marker to predict better patient response to radiochemotherapy in recessive model. However, larger prospective randomized trials will be required.
本荟萃分析旨在评估ERCC1 rs11615（C>T）基因多态性与患者对铂类化疗及放化疗的反应之间是否存在关联。
从PubMed和MEDLINE中筛选出版物。通过检查比值比（OR）和95%置信区间（CI）进行荟萃分析，以确定基因多态性与铂类化疗及放化疗反应之间的关联。
在我们的总体分析中，在五个比较模型中，ERCC1 rs11615（C>T）基因多态性与铂类化疗反应无关。在按种族进行的亚组分析中，在隐性模型（TT与CT/CC比较）中，ERCC1 rs11615（C>T）基因多态性显示与接受铂类化疗的白种人患者的客观反应显著相关（OR 0.696，95%CI 0.508 - 0.954，异质性 = 0.330），但在亚洲人群中未观察到这种关联。在隐性模型比较（TT与CC/CT比较）中，C等位基因与放化疗的更好反应显著相关（OR 0.724，95%CI 0.585 - 0.869，异质性 = 0.008）。按癌症类型进行的亚组分析显示，在两个比较模型中，ERCC1 rs11615的C等位基因在食管癌中预测了更好的反应（T与C比较：OR 0.756，95%CI 0.648 - 0.880，异质性 = 0.653；TT与TC/CC比较：OR 0.457，95%CI 0.306 - 0.684，异质性 = 0.723）。按种族进行的分层分析显示，在等位基因比较模型中白种人的反应更好（T与C比较：OR 0.895，95%CI 0.819 - 0.977，异质性 =
